This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cadence CEO Discusses Q3 2010 Results - Earnings Call Transcript

As you know, on November 2nd Cadence achieved a significant milestone with the approval by the FDA of OFIRMEV, a proprietary intravenous formulation of IV acetaminophen for the management of mild to moderate pain. The management of moderate to severe pain with adjunctive opioid analgesics and the reduction of fever, OFIRMEV is the first and only form of IV acetaminophen to be approved in the U.S.

In our pivotal clinical trials in patients undergoing hip or knee surgery, OFIRMEV resulted in significantly decreased pain intensity and reduced opioid consumption, as well as improved patient satisfaction when compared to placebo.

We firmly believe that OFIRMEV may benefit hospitalized patients by offering physicians a new non-opioid, non-NSAIDs treatment option for the management of pain and fever.

Our commercial leadership team led by Scott Byrd, our Chief Commercial Officer, and Randy St. Laurent, our VP of Sales, is excited about the positive feedback we’ve received about OFIRMEV from thought leaders across the country, as well as from our market research.

For example, surgeons and anesthesiologists surveyed in 2009 indicated that they would prescribe IV acetaminophen for more than 70% of patients experiencing post-operative pain.

As we have stated previously, we believe that OFIRMEV will achieve robust formulary adoption on the basis of its potential to fill unmet medical needs. In circumstances in which hospitals closely consider pharmacoeconomic benefits, we believe OFIRMEV’s value will be reinforced.

In particular, we’re encouraged by the potential to provide hospital formulary committees with published studies of IV acetaminophen that have demonstrated a reduction in opioid consumption, as well as decreased PACU time, post-surgical ambulation time and time to extubation in the ICU.

Our preparations for the launch of OFIRMEV early in the first quarter of 2010 are well underway. As we shared with you on Tuesday, immediately following the approval of OFIRMEV we initiated the process of hiring our sales team.

Read the rest of this transcript for free on seekingalpha.com

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs